<?xml version="1.0" encoding="UTF-8"?>
<p>The most common adverse effects associated with CQ and HCQ use are gastrointestinal disorders, hypoglycemia, and QT interval prolongation (after short term treatment), as well as cardiomyopathy and retinal toxicity (after long-term treatment) [
 <xref rid="B102-jcm-09-02084" ref-type="bibr">102</xref>]. Several concerns were raised regarding the safety profile of HCQ administered for COVID-19 treatment (the doses recommended in several guidelines for COVID-19 treatment—800 mg/day on day 1, followed by 400 mg/day for 4 days —are higher as compared with those administered conventionally for chronic therapies) in terms of cardiac toxicity and retinopathy [
 <xref rid="B101-jcm-09-02084" ref-type="bibr">101</xref>,
 <xref rid="B103-jcm-09-02084" ref-type="bibr">103</xref>]. Moreover, a retrospective study conducted on 95 hospitalized COVID-19 patients treated with CQ showed that 23% of the patients presented QT interval prolongation [
 <xref rid="B104-jcm-09-02084" ref-type="bibr">104</xref>]. A case report stated that CQ treatment induced Torsade de Pointes in a COVID-19 female patient [
 <xref rid="B105-jcm-09-02084" ref-type="bibr">105</xref>].
</p>
